Sangamo Therapeutics (SGMO) Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at ASH

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/13/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to Sangamo Therapeutics (SGMO) Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at ASH

Sangamo Announces Gene Therapy and Ex Vivo Gene-Edited Cell Therapy Data Presentations at the American Society of Hematology Annual Meeting

November 6, 2019 9:00 AM EST

BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, today announced that hemophilia A gene therapy clinical data and hemoglobinopathies ex vivo gene-edited cell therapy data will be featured in poster presentations at the 61st Annual Meeting of the American Society of Hematology (ASH). The ASH abstracts, which were submitted on August 3, 2019, were released online this morning. The conference will take place in Orlando, FL, from December 7-10, 2019.

Gene Therapy

Abstract #2060: Updated Follow-up of the Alta Study, a Phase 1/2, Open Label,... More